Celcuity CELC Stock
Celcuity Price Chart
Celcuity CELC Financial and Trading Overview
| Celcuity stock price | 16.05 USD |
| Previous Close | 10.57 USD |
| Open | 10.66 USD |
| Bid | 0 USD x 2200 |
| Ask | 0 USD x 3000 |
| Day's Range | 10.38 - 10.97 USD |
| 52 Week Range | 7.5 - 14.4 USD |
| Volume | 58.9K USD |
| Avg. Volume | 72.6K USD |
| Market Cap | 234.52M USD |
| Beta (5Y Monthly) | 0.600704 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.69 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.67 USD |
CELC Valuation Measures
| Enterprise Value | 110.64M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.0608363 |
| PEG Ratio (5 yr expected) | -0.15 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.9017094 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -2.501 |
Trading Information
Celcuity Stock Price History
| Beta (5Y Monthly) | 0.600704 |
| 52-Week Change | 25.64% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 14.4 USD |
| 52 Week Low | 7.5 USD |
| 50-Day Moving Average | 10.18 USD |
| 200-Day Moving Average | 10.3 USD |
CELC Share Statistics
| Avg. Volume (3 month) | 72.6K USD |
| Avg. Daily Volume (10-Days) | 54.63K USD |
| Shares Outstanding | 21.96M |
| Float | 9.69M |
| Short Ratio | 35.47 |
| % Held by Insiders | 26.63% |
| % Held by Institutions | 55.04% |
| Shares Short | 1.46M |
| Short % of Float | 8.43% |
| Short % of Shares Outstanding | 6.63% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -22.68% |
| Return on Equity (ttm) | -48.032% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -44232156 USD |
| Net Income Avi to Common (ttm) | -44646008 USD |
| Diluted EPS (ttm) | -2.52 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 157.5M USD |
| Total Cash Per Share (mrq) | 7.17 USD |
| Total Debt (mrq) | 36.04M USD |
| Total Debt/Equity (mrq) | 29.25 USD |
| Current Ratio (mrq) | 28.264 |
| Book Value Per Share (mrq) | 5.616 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -42942976 USD |
| Levered Free Cash Flow (ttm) | -27250780 USD |
Profile of Celcuity
| Country | United States |
| State | MN |
| City | Minneapolis |
| Address | 16305–36th Avenue North |
| ZIP | 55446 |
| Phone | 763 392 0767 |
| Website | https://www.celcuity.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 45 |
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Q&A For Celcuity Stock
What is a current CELC stock price?
Celcuity CELC stock price today per share is 16.05 USD.
How to purchase Celcuity stock?
You can buy CELC shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Celcuity?
The stock symbol or ticker of Celcuity is CELC.
Which industry does the Celcuity company belong to?
The Celcuity industry is Biotechnology.
How many shares does Celcuity have in circulation?
The max supply of Celcuity shares is 34.74M.
What is Celcuity Price to Earnings Ratio (PE Ratio)?
Celcuity PE Ratio is now.
What was Celcuity earnings per share over the trailing 12 months (TTM)?
Celcuity EPS is -2.69 USD over the trailing 12 months.
Which sector does the Celcuity company belong to?
The Celcuity sector is Healthcare.
Celcuity CELC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}